For treating advanced systemic mastocytosis (including aggressive systemic mastocytosis, systemic mastocytosis with an associated haematological neoplasm and mast cell leukaemia) in adults.

Avelumab plus axitinib can be used as an option for untreated advanced renal cell carcinoma (RCC) in adults, only if they have a favourable-risk status, as defined in the International Metastatic Renal Cell Carcinoma Database Consortium criteria. (NICE TA1120)

• as first- and second-line treatment only, when
• targeted treatments or immunotherapy are unsuitable, and
• chemotherapy would otherwise be offered.

Bevacizumab with fluoropyrimidine-based chemotherapy can only be used if the companies have an agreed price within the Medicines Procurement and Supply Chain.

With lenalidomide and dexamethasone is recommended, within its marketing authorisation, as an option for untreated multiple myeloma in adults, when an autologous stem celltransplant is unsuitable.

Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable TA1170

NICE TA1064: To treat primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults when systemic therapy is suitable.

Dostarlimab plus platinum-containing chemotherapy can be used as an option to treat primary advanced or recurrent endometrial cancer with microsatellite stability (MSS) or mismatch repair proficiency (MMRp) in adults when systemic treatment is suitable. (NICE TA1117)

With etoposide and either carboplatin or cisplatin is recommended as an option for
untreated extensive-stage small-cell lung cancer in adults if they have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Durvalumab with tremelimumab can be used, within its marketing authorisation, as an option for untreated advanced or unresectable hepatocellular carcinoma (HCC) in adults as per NICE TA1090.

Durvalumab can be used, within its marketing authorisation, as an option to treat limited-stage small-cell lung cancer that has not progressed after platinum-based chemoradiotherapy in adults as per NICE TA1099.

Durvalumab can be used, within its marketing authorisation, as an option with gemcitabine and cisplatin for neoadjuvant treatment, and then alone for adjuvant treatment, of muscle-invasive bladder cancer in adults, as per NICE TA1138

Durvalumab can be used, within its marketing authorisation, as an option for neoadjuvant and adjuvant treatment with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy, then alone as adjuvant treatment, for resectable gastric or gastro-oesophageal junction adenocarcinoma in adults. NICE TA1160

Enfortumab vedotin with pembrolizumab can be used, within its marketing authorisation, as an option for untreated unresectable or metastatic urothelial cancer in adults when platinum-based chemotherapy is suitable. NICE TA1097

Epcoritamab can be used as an option to treat relapsed or refractory follicular lymphoma in adults after 2 or more lines of systemic treatment, only if epcoritamab is stopped after 3 years of treatment or earlier if the lymphoma progresses, as per NICE TA1139 (Commissioned by NHS England).

For the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (R/R DLBCL), after two or more lines of systemic therapy.

Glofitamab plus gemcitabine and oxaliplatin can be used as an option to treat relapsed or refractory diffuse large B‑cell lymphoma not otherwise specified in adults when:

• they have had 1 line of treatment only, and

• they are not eligible for an autologous stem cell transplant. (NICE TA1113)

Isatuximab plus bortezomib, lenalidomide and dexamethasone can be used, within its marketing authorisation, as an option for untreated multiple myeloma in adults when an autologous stem cell transplant is unsuitable. NICE TA1098

For treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma in adults after 2 or more systemic treatments NICE TA947.

Nivolumab can be used as an option for neoadjuvant treatment with platinum-based chemotherapy, then alone as adjuvant treatment, for non-small-cell lung cancer (NSCLC) with a high risk of recurrence in adults whose tumours:

• are resectable (4 cm or more or node positive) and
• have no epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. (NICE TA1127)

Obecabtagene autoleucel (obe‑cel) can be used as an option to treat relapsed or refractory B‑cell precursor acute lymphoblastic leukaemia in people aged 26 years and over. (NICE TA1116)

For newly diagnosed FLT3-ITD-positive acute myeloid leukaemia (AML) in adults, when used:
with standard cytarabine and anthracycline chemotherapy as induction treatment, then
with standard cytarabine chemotherapy as consolidation treatment, then alone as maintenance treatment.

Talquetamab can be used as an option to treat relapsed and refractory multiple myeloma in adults when:

• they have had 3 or more lines of treatment including:
  • an immunomodulatory drug
  • a proteasome inhibitor, and
  • an anti-CD38 antibody, and

• the myeloma has progressed on the last treatment. (NICE TA1114)

For treating relapsed and refractory multiple myeloma in adults, only after 3 or more lines of treatment (including an immunomodulatory drug, a proteasome inhibitor and an anti-CD38 antibody) when the myeloma has progressed on the last treatment.

Ripretinib can be used, within its marketing authorisation, as an option to treat advanced gastrointestinal stromal tumours (GISTs) in adults after 3 or more kinase inhibitors, including imatinib as per NICE TA1146. (Commissioned by NHS England.

Zanidatamab can be used, within its marketing authorisation, to treat HER2-positive (defined as immunohistochemistry 3 [IHC3] positive) unresectable locally advanced or metastatic biliary tract cancer in adults after at least 1 line of systemic treatment, as per NICE TA1153 (Commissioned by NHS England).

Commissioned by NHSE

For treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment. NICE TA1164